List of NAVLIN Price & Access Software (formerly PriceRight by EVERSANA) Customers
Milwaukee, 53202, WI,
United States
Since 2010, our global team of researchers has been studying NAVLIN Price & Access Software (formerly PriceRight by EVERSANA) customers around the world, aggregating massive amounts of data points that form the basis of our forecast assumptions and perhaps the rise and fall of certain vendors and their products on a quarterly basis.
Each quarter our research team identifies companies that have purchased NAVLIN Price & Access Software (formerly PriceRight by EVERSANA) for Price Optimization from public (Press Releases, Customer References, Testimonials, Case Studies and Success Stories) and proprietary sources, including the customer size, industry, location, implementation status, partner involvement, LOB Key Stakeholders and related IT decision-makers contact details.
Companies using NAVLIN Price & Access Software (formerly PriceRight by EVERSANA) for Price Optimization include: Biogen, a United States based Life Sciences organisation with 7605 employees and revenues of $9.68 billion, Mirum Pharmaceuticals, Inc., a United States based Life Sciences organisation with 137 employees and revenues of $19.1 million, GENinCode, a United Kingdom based Healthcare organisation with 28 employees and revenues of $2.0 million, Iterum Therapeutics plc, a Ireland based Life Sciences organisation with 13 employees and revenues of $1.0 million and many others.
Contact us if you need a completed and verified list of companies using NAVLIN Price & Access Software (formerly PriceRight by EVERSANA), including the breakdown by industry (21 Verticals), Geography (Region, Country, State, City), Company Size (Revenue, Employees, Asset) and related IT Decision Makers, Key Stakeholders, business and technology executives responsible for the software purchases.
The NAVLIN Price & Access Software (formerly PriceRight by EVERSANA) customer wins are being incorporated in our Enterprise Applications Buyer Insight and Technographics Customer Database which has over 100 data fields that detail company usage of software systems and their digital transformation initiatives. Apps Run The World wants to become your No. 1 technographic data source!
Apply Filters For Customers
| Logo | Customer | Industry | Empl. | Revenue | Country | Vendor | Application | Category | When | SI | Insight | Insight Source |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
 |
Biogen | Life Sciences | 7605 | $9.7B | United States | EVERSANA | NAVLIN Price & Access Software (formerly PriceRight by EVERSANA) | Price Optimization | 2021 | n/a | In 2021, Biogen implemented NAVLIN Price & Access Software (formerly PriceRight by EVERSANA) as its Price Optimization platform. The deployment targeted global pricing and payer access workflows within Market Access and Reimbursement MA&R and Value and Access organizations, establishing a centralized pricing system to support cross-functional pricing decisioning and payer engagement processes. Configuration centered on the PriceRight PriCentric Navlin pricing model and included modules for IPR analysis, MEA and reimbursement modeling, price trend and price erosion analytics, corridor analysis, launch sequence planning LSO, and tender data management. The implementation also incorporated logistics and supply chain inputs, SOX compliance controls, and artificial intelligence capabilities for analytical modeling where indicated. Integrations were implemented with Veeva CRM, Veeva Vault and Salesforce to synchronize pricing inputs, tender records and payer access data with commercial engagement and document vault systems. NAVLIN Price & Access Software was configured to interoperate with these systems to align pricing models, contract deliverables and regulatory documentation across Biogen’s commercial technology stack. Operational coverage focused on Global Pricing teams within MA&R and Value and Access, supporting pricing strategy, payer access planning and reimbursement operations. Governance emphasized model management and compliance workflows to satisfy SOX requirements, with ongoing strategy and support retained by Biogen pricing and value and access teams. | |
 |
GENinCode | Healthcare | 28 | $2M | United Kingdom | EVERSANA | NAVLIN Price & Access Software (formerly PriceRight by EVERSANA) | Price Optimization | 2021 | n/a | In 2021 GENinCode implemented NAVLIN Price & Access Software (formerly PriceRight by EVERSANA) to support U.S. market access and pricing as part of a commercialization engagement with EVERSANA. This reflects GENinCode using NAVLIN Price & Access Software for Price Optimization aligned to market access and pricing business functions. NAVLIN Price & Access Software was configured to provide price optimization capabilities including configurable pricing rules, scenario modeling and access forecasting to inform launch pricing and reimbursement strategies. Configuration work focused on price and access models, list and net price scenario analysis, and decision workflows for commercial pricing governance. The implementation was embedded within EVERSANA's integrated commercialization services for the United States, enabling coordination between pricing models and channel management operations. Operational coverage targeted GENinCode's commercial and market access teams to support U.S. launch activities and payer engagement workflows. Governance was structured to centralize pricing decisions and standardize approval workflows across GENinCode and EVERSANA stakeholders, with NAVLIN Price & Access Software serving as the price optimization platform connecting pricing strategy to market access execution. The narrative captures GENinCode NAVLIN Price & Access Software Price Optimization for market access and channel management in the United States. | |
 |
Iterum Therapeutics plc | Life Sciences | 13 | $1M | Ireland | EVERSANA | NAVLIN Price & Access Software (formerly PriceRight by EVERSANA) | Price Optimization | 2025 | n/a | In 2025, Iterum Therapeutics plc engaged EVERSANA for U.S. commercialization services, and the use of NAVLIN Price & Access Software formerly PriceRight by EVERSANA is inferred from the announced market access and pricing activities to support a planned Q4 2025 U.S. launch. NAVLIN Price & Access Software is presented in the context of Price Optimization, and the engagement centers on market access, pricing strategy, sales and channel management for the United States market. Implementation scope focused on commercial and market access functions, where NAVLIN Price & Access Software would be configured to manage pricing models, access scenario analysis, reimbursement and payer strategy workflows, and contract and channel price structuring. Functional modules implied by the engagement align with Price Optimization capabilities such as list and net price simulation, scenario modeling for payer coverage, and governance workflows for pricing approvals and change control. Operational coverage is explicitly U.S. market access and pricing, with the platform inference tied to EVERSANA's delivery of commercialization services rather than a named systems integration. The deployment narrative indicates close alignment between Iterum commercial leads and EVERSANA market access teams to align pricing inputs with sales and channel management processes ahead of the Q4 2025 launch. Governance and rollout emphasis is on a U.S.-focused, launch-driven cadence that coordinates pricing governance, payer engagement sequencing, and pricing policy configuration in the NAVLIN Price & Access Software environment. Oversight is described as a joint commercialization governance model between Iterum Therapeutics plc and EVERSANA, applied to market access and pricing functions in support of the product launch. | |
 |
|
Life Sciences | 137 | $19M | United States | EVERSANA | NAVLIN Price & Access Software (formerly PriceRight by EVERSANA) | Price Optimization | 2020 | n/a |
|
|
Buyer Intent: Companies Evaluating NAVLIN Price & Access Software (formerly PriceRight by EVERSANA)
Discover Software Buyers actively Evaluating Enterprise Applications
| Logo | Company | Industry | Employees | Revenue | Country | Evaluated | ||
|---|---|---|---|---|---|---|---|---|
| No data found | ||||||||